Literature DB >> 20098637

Proteins That Underlie Neoplastic Progression of Ulcerative Colitis.

Teresa A Brentnall1, Sheng Pan, Mary P Bronner, David A Crispin, Hamid Mirzaei, Kelly Cooke, Yasuko Tamura, Tatiana Nikolskaya, Lellean Jebailey, David R Goodlett, Martin McIntosh, Ruedi Aebersold, Peter S Rabinovitch, Ru Chen.   

Abstract

Patients with ulcerative colitis (UC) have an increased risk for developing colorectal cancer. Because UC tumorigenesis is associated with genomic field defects that can extend throughout the entire colon, including the non-dysplastic mucosa; we hypothesized that the same field defect will include abnormally expressed proteins. Here we applied proteomics to study the protein expression of UC neoplastic progression. The protein profiles of colonic epithelium were compared from 1) UC patients without dysplasia (non-progressors); 2) none-dysplastic colonic tissue from UC patient with high-grade dysplasia or cancer (progressors); 3) high-grade dysplastic tissue from UC progressors and 4) normal colon. We identified protein differential expression associated with UC neoplastic progression. Proteins relating to mitochondria, oxidative activity, calcium-binding proteins were some of interesting classes of these proteins. Network analysis discovered that Sp1 and c-myc proteins may play roles in UC early and late stages of neoplastic progression, respectively. Two over-expressed proteins in the non-dysplastic tissue of UC progressors, CPS1 and S100P, were further confirmed by IHC analysis. Our study provides insight into the molecular events associated with UC neoplastic progression, which could be exploited for the development of protein biomarkers in fields of non-dysplastic mucosa that identify a patient's risk for UC dysplasia.

Entities:  

Year:  2009        PMID: 20098637      PMCID: PMC2809935          DOI: 10.1002/prca.200900061

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  43 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  Comparative proteomic studies on the pathogenesis of human ulcerative colitis.

Authors:  Sen-Yung Hsieh; Tsung-Chieh Shih; Chien-Yuh Yeh; Chun-Jung Lin; Yun-Ying Chou; Ying-Shiung Lee
Journal:  Proteomics       Date:  2006-10       Impact factor: 3.984

3.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

4.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

5.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

Authors:  T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

6.  ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis.

Authors:  Kaori Ishikawa; Keizo Takenaga; Miho Akimoto; Nobuko Koshikawa; Aya Yamaguchi; Hirotake Imanishi; Kazuto Nakada; Yoshio Honma; Jun-Ichi Hayashi
Journal:  Science       Date:  2008-04-03       Impact factor: 47.728

7.  Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci.

Authors:  Moritoshi Kinoshita; Masahiko Miyata
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

8.  S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2.

Authors:  Saeid Ghavami; Claus Kerkhoff; Walter J Chazin; Kamran Kadkhoda; Wenyan Xiao; Anne Zuse; Mohammad Hashemi; Mehdi Eshraghi; Klaus Schulze-Osthoff; Thomas Klonisch; Marek Los
Journal:  Biochim Biophys Acta       Date:  2007-11-07

9.  Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage.

Authors:  Rosa Ana Risques; Lisa A Lai; Teresa A Brentnall; Lin Li; Ziding Feng; Jasmine Gallaher; Margaret T Mandelson; John D Potter; Mary P Bronner; Peter S Rabinovitch
Journal:  Gastroenterology       Date:  2008-04-15       Impact factor: 22.682

10.  RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.

Authors:  Maren K Fuentes; Shraddha S Nigavekar; Thiruvengadam Arumugam; Craig D Logsdon; Ann Marie Schmidt; Juliet C Park; Emina H Huang
Journal:  Dis Colon Rectum       Date:  2007-08       Impact factor: 4.585

View more
  25 in total

Review 1.  Precancer in ulcerative colitis: the role of the field effect and its clinical implications.

Authors:  Kathryn T Baker; Jesse J Salk; Teresa A Brentnall; Rosa Ana Risques
Journal:  Carcinogenesis       Date:  2018-01-12       Impact factor: 4.944

Review 2.  Stat3: friend or foe in colitis and colitis-associated cancer?

Authors:  Jie Han; Arianne L Theiss
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

3.  Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia.

Authors:  Rajan K Bista; Teresa A Brentnall; Mary P Bronner; Christopher J Langmead; Randall E Brand; Yang Liu
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

4.  Mitochondria and tumor progression in ulcerative colitis.

Authors:  Cigdem Himmetoglu Ussakli; Anoosheh Ebaee; Jennifer Binkley; Teresa A Brentnall; Mary J Emond; Peter S Rabinovitch; Rosa Ana Risques
Journal:  J Natl Cancer Inst       Date:  2013-07-12       Impact factor: 13.506

5.  Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Authors:  Müge Çeliktas; Ichidai Tanaka; Satyendra Chandra Tripathi; Johannes F Fahrmann; Clemente Aguilar-Bonavides; Pamela Villalobos; Oliver Delgado; Dilsher Dhillon; Jennifer B Dennison; Edwin J Ostrin; Hong Wang; Carmen Behrens; Kim-Anh Do; Adi F Gazdar; Samir M Hanash; Ayumu Taguchi
Journal:  J Natl Cancer Inst       Date:  2017-03-01       Impact factor: 13.506

6.  BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.

Authors:  Bobak Parang; Andrew M Kaz; Caitlyn W Barrett; Sarah P Short; Wei Ning; Cody E Keating; Mukul K Mittal; Rishi D Naik; Mary K Washington; Frank L Revetta; J Joshua Smith; Xi Chen; Keith T Wilson; Thomas Brand; David M Bader; William P Tansey; Ru Chen; Teresa A Brentnall; William M Grady; Christopher S Williams
Journal:  Gut       Date:  2016-01-14       Impact factor: 23.059

7.  Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics.

Authors:  Damon May; Sheng Pan; David A Crispin; Keith Lai; Mary P Bronner; Jason Hogan; David M Hockenbery; Martin McIntosh; Teresa A Brentnall; Ru Chen
Journal:  J Proteome Res       Date:  2010-10-20       Impact factor: 4.466

8.  Up-regulation of mitochondrial chaperone TRAP1 in ulcerative colitis associated colorectal cancer.

Authors:  Ru Chen; Sheng Pan; Keith Lai; Lisa A Lai; David A Crispin; Mary P Bronner; Teresa A Brentnall
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Role of Hepatocyte Paraffin 1 antigen in the course of colorectal carcinogenesis.

Authors:  Riham M Abu-Zeid; Rola M Farid
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-09-10

Review 10.  Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis.

Authors:  Marco Scarpa; Ignazio Castagliuolo; Carlo Castoro; Anna Pozza; Melania Scarpa; Andromachi Kotsafti; Imerio Angriman
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.